Latest news and press releases about Cibus, Inc. (CBUS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name.
Price
| Price | $1.51 |
| Market Cap | $115M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 8.09 |
| EV / EBITDA | -2.29 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -320.60% |
| Return on Invested Capital | -17.82% |
| Return on Assets | -31.33% |
| Gross Margin | 45.73% |
| Operating Margin | -1240.90% |
| Net Margin | -2258.89% |
Related companies: ACRV · BMEA · CAMP · IMUX · MNOV · PMVP · RLMD
Explore sector: Healthcare · Biotechnology
More sections of CBUS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks